TrialBritish journal of clinical pharmacology2013

Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.

Malcolm Boyce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.